Valuation : Orion Oyj

Market Cap 1.12TCr 1.31TCr 1.06TCr 965.34Cr 1.81TCr 1,23200Cr 1.81TCr 12TCr 4.85TCr 63TCr 4.9TCr 4.79TCr 2,03700Cr P/E 2026 *
19.8x
P/E 2027 * 16.8x
Enterprise Value 1.11TCr 1.29TCr 1.05TCr 957.62Cr 1.79TCr 1,22300Cr 1.8TCr 12TCr 4.81TCr 63TCr 4.86TCr 4.76TCr 2,02100Cr EV / Sales 2026 *
5.31x
EV / Sales 2027 * 4.59x
Free-Float
90.5%
Yield 2026 *
2.44%
Yield 2027 * 2.72%
1 day+4.81%
6 months+4.81%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37.44
Extreme 37.44
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 1.31TCr
-0.88%-2.15%+58.05%+105.91% 1,02400Cr
-1.15%+2.68%+54.25%+71.29% 66TCr
-1.44%+0.38%+20.65%+75.54% 45TCr
+0.14%-0.47%+30.20%+40.61% 35TCr
-1.33%+4.72%+24.62%+47.60% 30TCr
-1.15%+0.30%-0.69%+11.83% 25TCr
-1.55%+1.11%+54.15%+72.13% 24TCr
-0.88%+1.15%-14.60%-54.84% 21TCr
-0.15%+3.65%+31.24%+100.90% 19TCr
Average -0.36%+1.09%+28.65%+52.33% 40.87TCr
Weighted average by Cap. -0.94%+0.55%+37.63%+67.00%

Financials

2026 *2027 *
Net sales 209.78Cr 243.79Cr 197.37Cr 180.3Cr 337.29Cr 23TCr 338.21Cr 2.33TCr 905.04Cr 12TCr 915.45Cr 895.48Cr 38TCr 237.37Cr 275.85Cr 223.33Cr 204.01Cr 381.65Cr 26TCr 382.69Cr 2.64TCr 1.02TCr 13TCr 1.04TCr 1.01TCr 43TCr
Net income 57Cr 66Cr 53Cr 49Cr 91Cr 6.21TCr 91Cr 629.16Cr 244.14Cr 3.19TCr 246.95Cr 241.57Cr 10TCr 67Cr 78Cr 63Cr 57Cr 107.39Cr 7.33TCr 107.68Cr 742.6Cr 288.16Cr 3.76TCr 291.47Cr 285.12Cr 12TCr
Net Debt -8.98Cr -10Cr -8.45Cr -7.71Cr -14Cr -984.86Cr -14Cr -100Cr -39Cr -505.3Cr -39Cr -38Cr -1.63TCr -33Cr -39Cr -31Cr -29Cr -54Cr -3.65TCr -54Cr -370.18Cr -143.65Cr -1.87TCr -145.3Cr -142.13Cr -6.04TCr
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
79.80EUR
Average target price
76.67EUR
Spread / Average Target
-3.93%

Quarterly revenue - Rate of surprise